Although other small molecules like 10058‐F4, 10074‐G5, KJ‐Pyr‐9, MYCMI‐6, MYCi361 and MYCi975 also inhibit Myc–Max interaction, their activity is limited to specific cancer types and has been associated with side effects.9, 10, 11, 12, 13, 14 Therefore, there is a growing demand for novel c‐Myc inhibitors capable of targeting a broader spectrum of cancers and facilitating combination therapies. The gene discussed is MAX; the disease is cancer.